Zura Bio (NASDAQ:ZURA) Trading 5.3% Higher – Time to Buy?

Zura Bio Limited (NASDAQ:ZURA)’s stock price rose 5.3% on Friday . The company traded as high as $5.52 and last traded at $5.5280. Approximately 150,021 shares traded hands during trading, a decline of 82% from the average session volume of 851,443 shares. The stock had previously closed at $5.25.

Wall Street Analyst Weigh In

Several research firms have weighed in on ZURA. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. Wall Street Zen downgraded Zura Bio from a “sell” rating to a “strong sell” rating in a research report on Sunday, July 12th. Oppenheimer cut their target price on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, March 20th. Wedbush restated an “outperform” rating and issued a $15.00 price target on shares of Zura Bio in a research report on Wednesday, July 1st. Finally, William Blair started coverage on shares of Zura Bio in a research note on Wednesday, July 8th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Price Performance

The company has a 50-day moving average of $4.47 and a 200 day moving average of $5.37. The company has a market cap of $525.16 million, a PE ratio of -5.08 and a beta of -0.03.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). Equities research analysts expect that Zura Bio Limited will post -0.76 EPS for the current year.

Institutional Trading of Zura Bio

A number of institutional investors have recently bought and sold shares of ZURA. Allworth Financial LP purchased a new position in Zura Bio during the fourth quarter worth $30,000. Scientech Research LLC purchased a new stake in shares of Zura Bio in the third quarter valued at $45,000. Dimensional Fund Advisors LP purchased a new stake in shares of Zura Bio in the fourth quarter valued at $123,000. Squarepoint Ops LLC bought a new stake in shares of Zura Bio in the 3rd quarter worth about $109,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Zura Bio in the 3rd quarter worth about $138,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.